| scholarly article | Q13442814 |
| P50 | author | Laura Lowe Furge | Q79830890 |
| Sarah M Glass | Q88763520 | ||
| P2093 | author name string | Rina Fujiwara | |
| Michael J Hicks | |||
| Michael J Glista | |||
| Jacqueline M Mills | |||
| Alexandria K Oswalt | |||
| Christi Cho | |||
| Cydney M Martell | |||
| Sharat S Kamath | |||
| Victoria Osorio-Vasquez | |||
| P2860 | cites work | Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. | Q46476314 |
| Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. | Q46702615 | ||
| Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. | Q46790144 | ||
| The star-allele nomenclature: retooling for translational genomics. | Q48690931 | ||
| Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug Metabolizing Enzymes as a Response to Redox Alteration. | Q49646816 | ||
| Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. | Q50979176 | ||
| Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. | Q54652897 | ||
| Kinetics of substrate reaction in the course of hydroperoxide-mediated inactivation of cytochrome P450 1A1 | Q71099331 | ||
| The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function | Q72075461 | ||
| Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization | Q72325253 | ||
| Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach | Q74301424 | ||
| Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity | Q87474450 | ||
| Structural Analysis of Mammalian Cytochrome P450 2B4 Covalently Bound to the Mechanism-Based Inactivator tert -Butylphenylacetylene: Insight into Partial Enzymatic Activity | Q27667508 | ||
| Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound | Q27677093 | ||
| The role of Thr268 in oxygen activation of cytochrome P450BM-3 | Q27729719 | ||
| Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 | Q28300073 | ||
| Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels | Q28543572 | ||
| THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE | Q29547810 | ||
| A semiempirical free energy force field with charge-based desolvation | Q29614316 | ||
| The ins and outs of cytochrome P450s. | Q30356342 | ||
| Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy | Q33237581 | ||
| Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators. | Q33680228 | ||
| Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes | Q34507636 | ||
| Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds | Q34575026 | ||
| Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. | Q34856974 | ||
| Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals | Q35001267 | ||
| Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction | Q35002484 | ||
| Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene | Q35579527 | ||
| Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity | Q35922156 | ||
| Peroxo-iron and oxenoid-iron species as alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by threonine-302 to alanine mutagenesis of cytochrome P450 2B4. | Q37600403 | ||
| Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. | Q37611786 | ||
| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation | Q38075335 | ||
| Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes. | Q38810337 | ||
| Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis | Q41306021 | ||
| Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms | Q42049770 | ||
| Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. | Q42103895 | ||
| Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine | Q43608395 | ||
| Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity | Q43737143 | ||
| Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C. | Q43794390 | ||
| Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine | Q43957740 | ||
| Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism | Q45118914 | ||
| Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation | Q45877729 | ||
| Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. | Q46046369 | ||
| Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders | Q46075268 | ||
| A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. | Q46188685 | ||
| Cumene hydroperoxide-mediated inactivation of cytochrome P450 2B1. Identification of an active site heme-modified peptide | Q46330563 | ||
| Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). | Q46375626 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1106-1117 | |
| P577 | publication date | 2018-05-21 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712 | |
| P478 | volume | 46 |
| Q91235937 | Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution | cites work | P2860 |
Search more.